150 related articles for article (PubMed ID: 30768629)
1. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
Lexchin J
PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629
[TBL] [Abstract][Full Text] [Related]
2. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
Lexchin J
BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Jenei K; Meyers DE
BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
[TBL] [Abstract][Full Text] [Related]
4. Reporting of financial conflicts of interest in clinical practice guidelines: a case study analysis of guidelines from the Canadian Medical Association Infobase.
Shnier A; Lexchin J; Romero M; Brown K
BMC Health Serv Res; 2016 Aug; 16(a):383. PubMed ID: 27528247
[TBL] [Abstract][Full Text] [Related]
5. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
Rose SL; Highland J; Karafa MT; Joffe S
JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
[TBL] [Abstract][Full Text] [Related]
6. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
[TBL] [Abstract][Full Text] [Related]
7. Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study.
Grundy Q; Imahori D; Mahajan S; Garner G; Timothy R; Sud A; Soklaridis S; Buchman DZ
PLoS One; 2023; 18(1):e0280110. PubMed ID: 36626363
[TBL] [Abstract][Full Text] [Related]
8. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
[TBL] [Abstract][Full Text] [Related]
9. Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
[TBL] [Abstract][Full Text] [Related]
10. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
11. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
Masucci L; Beca J; Sabharwal M; Hoch JS
Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
[TBL] [Abstract][Full Text] [Related]
12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
13. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
Lexchin J
BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
[TBL] [Abstract][Full Text] [Related]
14. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
Rawson NS
Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
[TBL] [Abstract][Full Text] [Related]
15. Researcher views about funding sources and conflicts of interest in nanotechnology.
McComas KA
Sci Eng Ethics; 2012 Dec; 18(4):699-717. PubMed ID: 21331667
[TBL] [Abstract][Full Text] [Related]
16. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
[TBL] [Abstract][Full Text] [Related]
17. The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.
Skedgel C
Curr Oncol; 2016 Oct; 23(5):322-328. PubMed ID: 27803596
[TBL] [Abstract][Full Text] [Related]
18. Guideline funding and conflicts of interest: article 4 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
Boyd EA; Akl EA; Baumann M; Curtis JR; Field MJ; Jaeschke R; Osborne M; Schünemann HJ;
Proc Am Thorac Soc; 2012 Dec; 9(5):234-42. PubMed ID: 23256165
[TBL] [Abstract][Full Text] [Related]
19. Conflict of interest in industry-sponsored economic evaluations: real or imagined?
Barbieri M; Drummond MF
Curr Oncol Rep; 2001 Sep; 3(5):410-3. PubMed ID: 11489241
[TBL] [Abstract][Full Text] [Related]
20. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
Lexchin J
Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
